BCBS Association’s Evidence Street Concludes HeartFlow FFRct Can Help Patients Avoid Unnecessary Invasive Procedures
HeartFlow, Inc. today announced that Blue Cross Blue Shield (BCBS) Association’s Evidence Street has issued a positive healthcare evidence review of the Company’s HeartFlow® FFRct.
The company reports this non-invasive technology is the first to provide insight into both the extent of coronary artery disease (CAD) and the impact the disease has on blood flow to the heart. It combines anatomic information from a coronary CT angiogram and physiology from HeartFlow FFRct to enable clinicians to select an appropriate and personalized treatment for each patient. The Evidence Street review assessed the technical performance, diagnostic accuracy and clinical utility of HeartFlow FFRct and determined that it provides a meaningful improvement in net health outcome when used to guide the care of patients with stable chest pain who are at intermediate risk of CAD and are being considered for invasive coronary angiography.
John H. Stevens, M.D., chief executive officer of HeartFlow points out, “This marks a major milestone achievement for HeartFlow and our FFRct technology because BCBS’s Evidence Street is among the world’s most rigorous health technology assessments and has significant global reach and influence.” “With BCBS insuring one in three Americans, substantially more patients with suspected CAD in the United States who are part of BCBS plans will be able to access this innovative non-invasive technology. HeartFlow FFRct also could now more rapidly become the standard of care, potentially improving clinical outcomes and saving global healthcare systems billions of dollars annually,” added Stevens.
Evidence Street provides healthcare technology evaluations for the BCBS Association, a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide healthcare coverage for 105 million Americans. Evidence Street’s assessment of HeartFlow FFRct, which is summarized in a 19-page report, concluded that “CCTA (coronary CT angiogram) with a selective FFRct strategy would likely lead to changes in management that would be expected to improve health outcomes by further limiting unnecessary ICA (invasive coronary angiography) testing.”
Evidence Street joins a growing number of organizations that support the use of HeartFlow FFRct as part of the diagnostic and treatment pathway for CAD. Several payers, including Aetna, which covers more than 46 million lives, have issued positive coverage decisions. In February, the National Institute for Health and Care Excellence (NICE) of the U.K.’s National Health Service, which covers 59 million lives, issued positive guidance, recommending the technology to help determine the cause of stable chest pain in patients. NICE concluded that HeartFlow FFRct is safe, has a high level of diagnostic accuracy, and may avoid the need for invasive coronary angiography, which is associated with risks. NICE further concluded that, compared to all other tests, use of HeartFlow FFRct is the most cost-effective solution as it avoids unnecessary invasive tests and treatment. Additionally, the American College of Cardiology (ACC) and American Heart Association (AHA) recently released updated Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease, which include the use of HeartFlow FFRct by healthcare providers in determining the appropriateness of revascularizations in many clinical scenarios.